All News

When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street.

1 June 2009

I have had the tremendous good fortune of strong leadership throughout my career.

1 June 2009

I joined Merck in 1996 as a customer account representative, processing pharmaceutical and vaccine orders for our direct customers.

Prior to joining Exelixis, I was an investment banker at Goldman Sachs, focusing on M&A and corporate finance.

It's hard to believe that Michelle Dipp has been in the industry for only five years considering her significant impact thus far on it.

FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop.

I've always loved the life sciences, and have been fortunate to have my career take place during a time of profound advances in biology.

If Carrolee Barlow has her way, the next new class of antidepressants will be branded BCI for BrainCells, Inc., the hot young San Diego biopharma riding the wave of neurogenesis.

Even in our crowd of underage overachievers, Luca Santarelli, MD, PhD, is a standout.

There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.

People define "work" differently. For some, it's making useful objects that you can see and touch.

I worked my way through college in the emergency room. It taught me a lot about life, death, and human suffering.

I began my career with an interest in medicine and pharmaceutical sciences.

The catalyst for innovation in the current environment is that people are living longer and the industry is not equipped to handle the significant burden that will place on the system.

The Primary Care Business Unit at Pfizer has taken some major steps to respond to the needs of our customers.

I started out as a cardiovascular primary care sales rep with Merck in the UK.

At 22, Stephanie Bova left the United States to teach English in Japan.

In 1990, Don Sawyer entered industry like many others do: as a sales representative.

FDA is seeking more resources to support compliance and oversight.

I trained as a journalist and worked at news organizations where all the reporters wanted to cover politics and crime.

In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.

28 May 2009

28 May 2009

1 June 2009

Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.

21 May 2009

Neil Darwent and Roger Cooper of GSK Biologicals talk to Pharm Exec Europe about the company's new, state-of-the-art approach to clinical trials in Africa.

US pharma CEO salaries are still dwarfing the earnings of their European counterparts, but, with the industry and the economy currently in crisis, Jacky Law asks how long this can continue.